LASSBio-1632
Product Specifications
UNSPSC Description
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion[1].
Target Antigen
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lassbio-1632.html
Solubility
10 mM in DMSO
Smiles
CC1=CC2=C(C=C1S(N(/N=C/C3=CC=C(C(OC)=C3)OC)C)(=O)=O)OCO2
Molecular Weight
392.43
References & Citations
[1]Isabelle Karine da Costa Nunes, et al. Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. Eur J Med Chem. 2020 Jul 18;204:112492.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-131340/LASSBio-1632-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-131340/
Clinical Information
No Development Reported
CAS Number
3029936-02-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7022123-01 0.02 mg
Recombinant Phodopus sungorus NADH-ubiquinone oxidoreductase chain 4 (MT-ND4)
Ask
View Details MBS7022123-02 0.1 mg
Recombinant Phodopus sungorus NADH-ubiquinone oxidoreductase chain 4 (MT-ND4)
Ask
View Details 
MBS7022123-03 5x 0.1 mg
Recombinant Phodopus sungorus NADH-ubiquinone oxidoreductase chain 4 (MT-ND4)
Ask
View Details